Patents by Inventor Michael J. Robarge

Michael J. Robarge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9096520
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: August 4, 2015
    Assignee: ABT Holding Company
    Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
  • Publication number: 20140206672
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).
    Type: Application
    Filed: March 19, 2014
    Publication date: July 24, 2014
    Applicant: ABT Holding Company
    Inventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
  • Publication number: 20140206739
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Application
    Filed: March 21, 2014
    Publication date: July 24, 2014
    Applicant: ABT Holding Company
    Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
  • Patent number: 8716324
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: May 6, 2014
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
  • Patent number: 8716276
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: May 6, 2014
    Assignee: Athersys, Inc.
    Inventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
  • Publication number: 20120252859
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Application
    Filed: June 18, 2012
    Publication date: October 4, 2012
    Applicant: ATHERSYS, INC.
    Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
  • Patent number: 8232311
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: July 31, 2012
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
  • Patent number: 8012997
    Abstract: The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-? in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: September 6, 2011
    Assignee: Celgene Corporation
    Inventors: Michael J. Robarge, Roger Shen-Chu Chen, George W. Muller, Hon-Wah Man
  • Patent number: 7981919
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: July 19, 2011
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, David C. Bom, Michael J. Robarge
  • Publication number: 20110172283
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Application
    Filed: March 25, 2011
    Publication date: July 14, 2011
    Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
  • Publication number: 20110112072
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).
    Type: Application
    Filed: January 12, 2011
    Publication date: May 12, 2011
    Inventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
  • Patent number: 7935830
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: May 3, 2011
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
  • Patent number: 7893051
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: February 22, 2011
    Assignee: Athersys, Inc.
    Inventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
  • Publication number: 20100190772
    Abstract: The present invention generally relates to compounds and pharmaceutical compositions containing the compounds. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Application
    Filed: April 1, 2010
    Publication date: July 29, 2010
    Inventors: Youssef L. Bennani, Michael J. Robarge, David C. Bom, Norbert Varga, Lawrence N. Tumey
  • Patent number: 7718647
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: May 18, 2010
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Michael J. Robarge, David C. Bom, Norbert Varga, Lawrence N. Tumey
  • Publication number: 20090286986
    Abstract: The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-? in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.
    Type: Application
    Filed: July 23, 2009
    Publication date: November 19, 2009
    Inventors: Michael J. Robarge, Roger Shen-Chu Chen, George W. Muller, Hon-Wah Man
  • Publication number: 20090239925
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Application
    Filed: June 4, 2009
    Publication date: September 24, 2009
    Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
  • Patent number: 7576104
    Abstract: The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-? in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: August 18, 2009
    Assignee: Celgene Corporation
    Inventors: Michael J. Robarge, Roger Shen-Chu Chen, George W. Muller, Hon-Wah Man
  • Publication number: 20090069365
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Application
    Filed: August 5, 2008
    Publication date: March 12, 2009
    Inventors: Youssef L. Bennani, David C. Bom, Michael J. Robarge
  • Patent number: 7470723
    Abstract: The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more Diphenylethylene Compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more Diphenylethylene Compounds. The present invention further relates to articles of manufacture and kits comprising one or more Diphenylethylene Compounds.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: December 30, 2008
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Faribourz Payvandi, Ling H. Zhang, Michael J. Robarge, Roger Chen, Hon-Wah Man, Alexander L. Ruchelman